advertising
-
1
Lindeman RD, Tobin J, Shock NW: Association between blood pressure and the rate of decline in renal function with age. .Kidney Int 26::861. ,1984. .
-
2
Rodriguez-Puyol D: The aging kidney. .Kidney Int 54:: 2247. ,1998. .
-
3
Thadhani R, Pascual M, Bonventre JV: Acute renal failure. .N Engl J Med 334::1448. ,1996. .
-
4
Hou SH, Bushinsky DA, Wish JB, et al: Hospital-acquired renal insufficiency: a prospective study. .Am J Med 74::243. ,1983. .
-
5
Kaufman J, Dhakal M, Patel B, et al: Community-acquired acute renal failure. .Am J Kidney Dis 17::191. ,1991. .
-
6
Shusterman N, Strom BL, Murray TG, et al: Risk factors and outcome of hospital-acquired acute renal failure: clinical epidemiologic study. .Am J Med 83::65. ,1987. .
-
7
Novis BK, Roizen MF, Aronson S, et al: Association of preoperative risk factors with postoperative acute renal failure. .Anesth Analg 78::143. ,1994. .
-
8
Corwin HL, Teplick RS, Schreiber MJ, et al: Prediction of outcome in acute renal failure. .Am J Nephrol 7::8. ,1987. .
-
9
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. .Am J Kidney Dis 39 (suppl 1)::S1. ,2002. .
-
10
Allon M: Hyperkalemia in end-stage renal disease: mechanisms and management. .J Am Soc Nephrol 6:: 1134. ,1995. .
-
11
Delmez JA, Slatopolsky E: Hyperphosphatemia: its consequences and treatment in chronic renal failure. .Am J Kidney Dis 19::303. ,1992. .
-
12
Alpern RJ, Sakhaee K: Clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. .Am J Kidney Dis 29::291. ,1997. .
-
13
Coresh J, Astor BC, Greene T, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. .Am J Kidney Dis 41::1. ,2003. .
-
14
Adamson JW, Eschbach JW: Erythropoietin for end-stage renal disease. .N Engl J Med 339::625. ,1998. .
-
15
Eberst ME, Berkowitz LR: Hemostasis in renal disease: pathophysiology and management. .Am J Med 96::168. ,1994. .
-
16
Weinberg MS, Weinberg AJ, Zappe DH: Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. .J Renin Angiotensin Aldosterone Syst 1::217. ,2000. .
-
17
Weinberg MS, Weinberg AJ, Cord R, et al: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. .J Renin Angiotensin Aldosterone Syst 2::196. ,2001. .
-
18
Tepel M, Van Der Giet M, Schwarzfeld C, et al: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. .N Engl J Med 343::180. ,2000. .
Acute and Chronic Renal Failure
Search for other papers by Jonathan Costa in
Current site
Google Scholar
PubMed
Search for other papers by Robert S. Crausman in
Current site
Google Scholar
PubMed
Search for other papers by Marc S. Weinberg in
Current site
Google Scholar
PubMed
Renal failure is defined as a deterioration of kidney function that results in the retention of nitrogenous waste products. It is increasingly prevalent in older populations, individuals with diabetes or hypertension, and postoperative patients. Therefore, podiatric physicians caring for these populations can expect to encounter this condition frequently. This article describes the epidemiology, causes, complications, and appropriate evaluation of renal failure relevant to a practicing podiatric physician. Also highlighted are treatment considerations, renal dosing of medications, and prevention of contrast nephropathy. (J Am Podiatr Med Assoc 94(2): 168-176, 2004)
advertising
